報價延遲最少15分鐘:2026/03/29 19:30 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
23.53 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.83/-0.22
|
|
企業價值
769.53M
|
| 資產負債 |
|
每股賬面淨值
15.84
|
| 現金流量 |
|
現金流量率
0.09
|
| 損益表 |
|
收益
344.23M
|
|
每股收益
6.46
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests. |
